Edition:
United Kingdom

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

5.39USD
23 May 2018
Change (% chg)

$0.04 (+0.75%)
Prev Close
$5.35
Open
$5.36
Day's High
$5.45
Day's Low
$5.35
Volume
36,400
Avg. Vol
104,614
52-wk High
$7.67
52-wk Low
$3.68

Select another date:

Thu, May 3 2018

BRIEF-Aratana Therapeutics Q1 Loss Per Share $0.19

* ARATANA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Engaged Capital Reports 5.2 Pct Stake In Aratana Therapeutics Inc, As Of April 4, 2018 SEC Filing

* ENGAGED CAPITAL LLC SAYS PURCHASED ARATANA THERAPEUTICS' SHARES BASED ON BELIEF THAT THE SHARES, WHEN PURCHASED, WERE UNDERVALUED

BRIEF-Aratana Therapeutics Reports Q4 Loss Per Share $0.37

* ARATANA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Aratana Therapeutics Expands Therapeutic Candidate Pipeline

* ARATANA THERAPEUTICS EXPANDS THERAPEUTIC CANDIDATE PIPELINE

BRIEF-Elanco, Aratana Announce Marketing Authorization Of Galliprant In Europe

* ELANCO, ARATANA ANNOUNCE MARKETING AUTHORIZATION OF GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE Source text for Eikon: Further company coverage:

BRIEF-Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic

* ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC

BRIEF-Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria

* ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY

BRIEF-Aratana Therapeutics Announces Proposed Public Offering

* ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

Select another date: